News & Press

Hack The Box University CTF 2021

Fri, 15 Oct 2021 14:05:27 GMT

Universities around the world, assemble!

Welcome back! It’s been a year already… Did you rest? Did you push your skills to the top? Are you ready for our iconic event? Bring it ON!

Hack The Box University CTF 2021 is HERE!

Every year we gather university students from all over the world to compete in our university CTF, which provides a hands-on learning experience for students of all skill levels! With prizes that give even more learning opportunities!

Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion

Wed, 11 Dec 2019 19:06:12 GMT

Proprietary immuno-oncology (IO) platform synergistic with Sanofi’s existing therapeutic platforms
Lead asset THOR-707 (“not-alpha” IL-2) being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations
Pre-clinical pipeline for oncology and autoimmune disorders

PARIS and San Diego, California – December 9, 2019 – Sanofi and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis). The transaction was unanimously approved by both the Sanofi and Synthorx Boards of Directors.

Read the full press release here.

Satsuma Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock

Thu, 12 Sep 2019 17:27:13 GMT

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $82.5 million, before the underwriting discounts and commissions. All of the shares of common stock are being offered by Satsuma. The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 825,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Satsuma's common stock has been approved for listing on The Nasdaq Global Market and is expected to begin trading under the ticker symbol "STSA" on September 13, 2019. The offering is expected to close on September 17, 2019, subject to customary closing conditions.

Please find the full press release here.